NCT00004070View on ClinicalTrials.gov

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 31, 1999

Primary Completion Date

November 30, 2000

Study Completion Date

December 31, 2000

Conditions
Head and Neck Cancer
Interventions
BIOLOGICAL

IL-12

Trial Locations (2)

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Dana-Farber Cancer Institute

OTHER